{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:02:46Z","timestamp":1793689366751,"version":"4.5.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"name":"National Key Research and Development Program of China","award":["2020YFC2008306"],"award-info":[{"award-number":["2020YFC2008306"]}]},{"name":"Bi ke he zhong da zhuan xiang","award":["2023-2-3"],"award-info":[{"award-number":["2023-2-3"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the predictive performance of published lamotrigine (LTG) population pharmacokinetic (PPK) models using an external data set of Chinese patients with epilepsy or postneurosurgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In total, 348 concentration measurements from 94 Chinese children and 254 Chinese adults with epilepsy or postneurosurgery were used for external validation. Data on published LTG PPK models were obtained from the literature. The predictability of the models was assessed using prediction-based diagnostics (eg, F20 and F30), simulation-based diagnostics, and Bayesian forecasting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The results of prediction-based diagnostics for all 10 models were unsatisfactory. The best-performing models, characterized as one-compartment models with nonlinear pharmacokinetics, incorporated weight as a key covariate and included interindividual variability for both clearance and volume of distribution. These models achieved exceptional predictive performance in simulation-based diagnostics and Bayesian forecasting, with IF\n                      <jats:sub>30<\/jats:sub>\n                      values of 90.32%, 97.23%, and 99.61%, respectively, demonstrating superior precision and accuracy. Bayesian forecasting improved the predictive accuracy of 80% of the models, significantly enhancing model predictability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The published PPK models show extensive variation in predictive performance for extrapolation among Chinese patients with epilepsy or postneurosurgery. The lack of key covariates (such as concomitant medications, genetic polymorphisms, and age stratification) and fixed parameters of volume of distribution and absorption rate constant in the PPK modeling of LTG may explain its unsatisfactory predictive performance. Bayesian forecasting significantly improves the model predictability and may help individualize LTG dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001322","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:00:10Z","timestamp":1741863610000},"page":"820-827","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["External Validation of Population Pharmacokinetic Models of Lamotrigine in Patients with Epilepsy or Postneurosurgery"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0997-7141","authenticated-orcid":false,"given":"Yunshu","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Bijie Maternal and Child Health Hospital, Bijie City, Guizhou Province, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Bijie Maternal and Child Health Hospital, Bijie City, Guizhou Province, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","article-title":"Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/epi.13057","article-title":"Summary of recommendations for the management of infantile seizures: task force report for the ILAE commission of pediatrics Epilepsia","volume":"56","author":"Wilmshurst","year":"2015","journal-title":"Epilepsia"},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/FPC.0000000000000397","article-title":"PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics","volume":"30","author":"Mitra-Ghosh","year":"2020","journal-title":"Pharmacogenet Genomics"},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv Drug Deliv Rev."},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2000.00237.x","article-title":"Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children","volume":"50","author":"Chen","year":"2000","journal-title":"Br J Clin Pharmacol."},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","article-title":"Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy","volume":"39","author":"Grasela","year":"1999","journal-title":"J Clin Pharmacol."},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/aps.2012.118","article-title":"Population pharmacokinetics of lamotrigine in Chinese children with epilepsy","volume":"33","author":"He","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data","volume":"43","author":"Hussein","year":"1997","journal-title":"Br J Clin Pharmacol."},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","article-title":"Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy","volume":"30","author":"Rivas","year":"2008","journal-title":"Ther Drug Monit."},{"issue":"8","key":"R15-20251107","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40262-018-0660-7","article-title":"Correction to: effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials","volume":"57","author":"van Dijkman","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R16-20251107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00228-016-2190-2","article-title":"Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy","volume":"73","author":"Zhang","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/acn3.29","article-title":"Model-based lamotrigine clearance changes during pregnancy: clinical implication","volume":"1","author":"Polepally","year":"2014","journal-title":"Ann Clin Transl Neurol."},{"key":"R18-20251107","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","article-title":"Population pharmacokinetics of lamotrigine in elderly patients","volume":"48","author":"Punyawudho","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"R19-20251107","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters","volume":"82","author":"Milosheska","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R20-20251107","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0000000000001207","article-title":"Population pharmacokinetics of lamotrigine and its N2-glucuronide metabolite in Chinese patients with epilepsy","volume":"46","author":"Yang","year":"2024","journal-title":"Ther Drug Monit."},{"key":"R21-20251107","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R22-20251107","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/npr2.12196","article-title":"Neuropharmacology of antiseizure drugs","volume":"41","author":"Hakami","year":"2021","journal-title":"Neuropsychopharmacol Rep."},{"key":"R23-20251107","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","article-title":"Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy","volume":"2","author":"Biton","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R24-20251107","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1528-1157.1997.tb01128.x","article-title":"Quality of life of people with epilepsy: a European study","volume":"38","author":"Baker","year":"1997","journal-title":"Epilepsia"},{"key":"R25-20251107","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"L\u00f6scher","year":"2011","journal-title":"Epilepsia"},{"key":"R26-20251107","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199310000-00005","article-title":"Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control","volume":"15","author":"Jelliffe","year":"1993","journal-title":"Ther Drug Monit."},{"key":"R27-20251107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.seizure.2020.07.014","article-title":"Sources of lamotrigine pharmacokinetic variability: a systematic review of population pharmacokinetic analyses","volume":"82","author":"Methaneethorn","year":"2020","journal-title":"Seizure"},{"key":"R28-20251107","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-012-1311-9","article-title":"Population pharmacokinetics of lamotrigine in Indian epileptic patients","volume":"69","author":"Mallaysamy","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R29-20251107","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00228-024-03746-x","article-title":"Fixed parameters in the population pharmacokinetic modeling of valproic acid might not be suitable: external validation in Chinese adults with epilepsy or after neurosurgery","volume":"80","author":"Wu","year":"2024","journal-title":"Eur J Clin Pharmacol."},{"key":"R30-20251107","doi-asserted-by":"crossref","first-page":"115437","DOI":"10.1016\/j.jpba.2023.115437","article-title":"Simultaneous determination of 24 antiepileptic drugs and their active metabolites in human plasma by UHPLC-MS\/MS","volume":"232","author":"Jiang","year":"2023","journal-title":"J Pharm Biomed Anal."},{"key":"R31-20251107","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s11095-022-03273-3","article-title":"Population pharmacokinetic evaluation with external validation of tacrolimus in Chinese primary nephrotic syndrome patients","volume":"39","author":"Yang","year":"2022","journal-title":"Pharm Res."},{"key":"R32-20251107","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"R33-20251107","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed."},{"key":"R34-20251107","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","article-title":"Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients","volume":"69","author":"Singkham","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R35-20251107","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0000000000000563","article-title":"A population pharmacokinetic-pharmacogenetic model of lamotrigine in Chinese children with epilepsy","volume":"40","author":"Chen","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R36-20251107","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/ALN.0000000000002968","article-title":"Perioperative acute kidney injury","volume":"132","author":"Gumbert","year":"2020","journal-title":"Anesthesiology"},{"key":"R37-20251107","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12028-022-01630-z","article-title":"Kidney dysfunction after traumatic brain injury: pathophysiology and general management","volume":"38","author":"De Vlieger","year":"2023","journal-title":"Neurocrit Care"},{"key":"R38-20251107","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R39-20251107","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","article-title":"Population pharmacokinetics of lamotrigine","volume":"23","author":"Chan","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R40-20251107","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.xphs.2020.05.030","article-title":"Dosing recommendations based on population pharmacokinetics of lamotrigine in Mexican adult patients with epilepsy","volume":"109","author":"Ch\u00e1vez-Castillo","year":"2020","journal-title":"J Pharm Sci."},{"key":"R41-20251107","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1124\/dmd.107.015271","article-title":"Possible bioactivation pathways of lamotrigine","volume":"35","author":"Lu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R42-20251107","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003088-200645100-00001","article-title":"Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics","volume":"45","author":"Chen","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R43-20251107","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/humu.9432","article-title":"Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus","volume":"27","author":"Thomas","year":"2006","journal-title":"Hum Mutat."},{"key":"R44-20251107","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s11010-022-04637-4","article-title":"Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma","volume":"478","author":"Matsumoto","year":"2023","journal-title":"Mol Cel Biochem"},{"key":"R45-20251107","first-page":"303","article-title":"UGT2B7 c.-161C>T polymorphism frequency in Croatian population","volume":"73","author":"Bo\u017eina","year":"2022","journal-title":"Arh Hig Rada Toksikol"},{"key":"R46-20251107","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s13318-024-00894-4","article-title":"Influence of UGT2B7, UGT1A4 and ABCG2 polymorphisms on the pharmacokinetics and therapeutic efficacy of lamotrigine in patients with epilepsy","volume":"49","author":"Yang","year":"2024","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R47-20251107","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s11096-019-00864-w","article-title":"Estimation of apparent clearance of valproic acid in adult Saudi patients","volume":"41","author":"Alqahtani","year":"2019","journal-title":"Int J Clin Pharm."},{"key":"R48-20251107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2020.00177","article-title":"The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib","volume":"11","author":"Buclin","year":"2020","journal-title":"Front Pharmacol."},{"key":"R49-20251107","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:36Z","timestamp":1762542036000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001322","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"2024-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}